USTEKINUMAB, USTEKINUMAB, deucravacitinib
IM011-1130
Approved small_molecule active
Quick answer
USTEKINUMAB, USTEKINUMAB, deucravacitinib for Moderate to Severe Plaque Psoriasis is a Approved program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Moderate to Severe Plaque Psoriasis
- Phase
- Approved
- Modality
- small_molecule
- Status
- active